Takeda Pharma announces results from its Phase 3 TOURMALINE-MM2 trial
Category: #health  By Pankaj Singh  Date: 2020-09-11
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Takeda Pharma announces results from its Phase 3 TOURMALINE-MM2 trial

Takeda Pharmaceutical Company Ltd, a renowned Japanese pharmaceutical company, has reportedly announced the outcome of Phase 3 TOURMALINE-MM2 trial that assesses the combination of ixazomib (NINLARO) and lenalidomide, dexamethasone versus dexamethasone and lenalidomide with placebo in patients suffering from multiple myeloma and are not eligible to undergo an autologous stem cell transplant.

The data was presented at the SOHO (Society of Hematologic Oncology) virtual scientific meeting held on September 9, 2020. The new trial discovered that adding NINLARO to dexamethasone and lenalidomide led to a 13.5-month rise in the median PFS (progression-free survival). However, the study did not fulfill the statistical significance threshold and also did not meet the PFS primary endpoint.

Lead author and principal investigator of the TOURMALINE-MM2 trial, Thierry Facon, MD, Lille University Hospital stated that there is a particular need in the multiple myeloma patients as presently there are no authorized all-oral treatment options that are proteasome inhibitor based.

Facon further added that results from the Phase 3 trial are crucial for the patient population and throughout multiple subgroups like patients suffering from high-risk cytogenetics. The company expects that the newly found data would help for future research and also progress multiple myeloma community further.

Christopher Arendt, Head of Takeda’s Oncology Therapeutic Unit, stated that the company hopes that the results from the Phase 3 trial would foster constructive conversations and also help drive future research efforts, especially for patients that can greatly benefit from a proteasome inhibitor-based and all-oral combination which helps to preserve the quality of life.

Arendt further added that the company remains committed to working towards the treatment of multiple myeloma community and also looks forward to providing mature data from the company’s ongoing Phase 3 studies related to multiple myeloma maintenance.

Source credit: https://www.businesswire.com/news/home/20200909005113/en/Takeda-Announces-Results-Phase-3-Clinical-Trial



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

PCS Software adds new contactless features to expand TMS platform

PCS Software adds new contactless features to expand TMS platform

By Pankaj Singh

  • With this addition, it is now possible for PCS consumers to effectively manage their workflows using their mobile devices
  • Document digitization has...

ODP teams up with Microsoft to support shared & new B2B customers

ODP teams up with Microsoft to support shared & new B2B customers

By Pankaj Singh

The ODP Corporation, an American retail company, has recently announced the expansion of its long-standing relationship with Microsoft. The two companies are planning to boost efficiencies and growth of their shared as...

Gannex reveals positive data from ASC41 clinical study in 20 subjects

Gannex reveals positive data from ASC41 clinical study in 20 subjects

By Pankaj Singh

Ascletis Pharma Inc.’s wholly-owned company, Gannex, has reportedly announced the positive clinical data from its ASC41 trial conducted among overweight and obese subjects. The active metabolite of this liver-tar...